Literature DB >> 31966082

miR-519 regulates the proliferation of breast cancer cells via targeting human antigen R.

Lili Ren1, Yong Li1, Qun Zhao1, Liqiao Fan1, Bibo Tan1, Aimin Zang2, Hua Yang2.   

Abstract

Breast cancer is one of the most prevalent types of cancer among women that leads to millions of deaths worldwide every year. The mechanisms of breast cancer pathogenesis remain unclear. It has been reported that aberrant expression of miR-519, is associated with breast cancer development; however, the effects of miR-519 on breast cancer cell proliferation remain unknown. Therefore, the present study aimed to determine whether miR-519 could regulate breast cancer cell proliferation. A total of 20 pairs of primary breast cancer and adjacent normal tissues were collected from patients with breast cancer. miR-519 expression level was determined by reverse transcription-quantitative polymerase chain reaction. Furthermore, miR-519 mimics or inhibitors were transfected into breast cancer MCF-7 cells in order to up- or downregulate miR-519 expression. Subsequently, human antigen R (HUR), BCL-2 and BAX protein levels were analyzed by western blotting. MCF-7 cell proliferation was assessed using MTT and colony formation assays. A luciferase assay was performed to verify whether miR-519 could directly bind to HUR mRNA. The results demonstrated that miR-519 expression level was lower in primary breast cancer tissues compared with adjacent normal tissues. Furthermore, miR-519 overexpression and downregulation inhibited and stimulated MCF-7 cell proliferation, respectively. In addition, the results from luciferase assay demonstrated that HUR was a target of miR-519. HUR overexpression could reverse the effect of miR-519 mimics on MCF-7 cell proliferation, whereas HUR silencing could rescue the effect of miR-519 inhibitors on MCF-7 cell proliferation. These findings suggested that miR-519 may regulate MCF-7 cell proliferation by targeting HUR.
Copyright © 2020, Spandidos Publications.

Entities:  

Keywords:  BAX; BCL-2; breast cancer; human antigen R; miR-519

Year:  2019        PMID: 31966082      PMCID: PMC6956239          DOI: 10.3892/ol.2019.11230

Source DB:  PubMed          Journal:  Oncol Lett        ISSN: 1792-1074            Impact factor:   2.967


  40 in total

1.  Growth inhibition by miR-519 via multiple p21-inducing pathways.

Authors:  Kotb Abdelmohsen; Subramanya Srikantan; Kumiko Tominaga; Min-Ju Kang; Yael Yaniv; Jennifer L Martindale; Xiaoling Yang; Sung-Soo Park; Kevin G Becker; Murugan Subramanian; Stuart Maudsley; Ashish Lal; Myriam Gorospe
Journal:  Mol Cell Biol       Date:  2012-04-30       Impact factor: 4.272

2.  Dual-Targeting of miR-124-3p and ABCC4 Promotes Sensitivity to Adriamycin in Breast Cancer Cells.

Authors:  Di Hu; Mengquan Li; Jing Su; Keke Miao; Xinguang Qiu
Journal:  Genet Test Mol Biomarkers       Date:  2019-02-26

Review 3.  Epidemiology, major risk factors and genetic predisposition for breast cancer in the Pakistani population.

Authors:  Uzma Shaukat; Muhammad Ismail; Nasir Mehmood
Journal:  Asian Pac J Cancer Prev       Date:  2013

4.  Downregulation of miroRNA-141 mediates acquired resistance to trastuzumab and is associated with poor outcome in breast cancer by upregulating the expression of ERBB4.

Authors:  Guodong Han; Ni Qiu; Kai Luo; Hongling Liang; Hongsheng Li
Journal:  J Cell Biochem       Date:  2019-02-11       Impact factor: 4.429

5.  Role of discoidin domain receptor 2 (DDR2) and microRNA-182 in survival of women with high-grade serous ovarian cancer.

Authors:  Susana Ramalho; Liliana Al De Angelo Andrade; Cássio Cardoso Filho; Rodrigo de Andrade Natal; Marina Pavanello; Amanda Canato Ferracini; Luis Felipe Sallum; Luis Otávio Sarian; Sophie Derchain
Journal:  Tumour Biol       Date:  2019-01

6.  PKM2 uses control of HuR localization to regulate p27 and cell cycle progression in human glioblastoma cells.

Authors:  Joydeep Mukherjee; Shigeo Ohba; Wendy L See; Joanna J Phillips; Annette M Molinaro; Russell O Pieper
Journal:  Int J Cancer       Date:  2016-03-02       Impact factor: 7.396

7.  Prevalence of depression in breast cancer survivors: a systematic review of observational studies.

Authors:  Nor Zuraida Zainal; Nik Ruzyanei Nik-Jaafar; Azlin Baharudin; Zuraida Ahmad Sabki; Chong Guan Ng
Journal:  Asian Pac J Cancer Prev       Date:  2013

8.  Interaction between C2ORF68 and HuR in human colorectal cancer.

Authors:  Zhaoxu Lv; Kunyan He; Lihong Shi; Kai Shi; Tingting Jiang; Yao Chen
Journal:  Oncol Rep       Date:  2019-01-21       Impact factor: 3.906

9.  CircSETD3 (Hsa_circ_0000567) acts as a sponge for microRNA-421 inhibiting hepatocellular carcinoma growth.

Authors:  Liangliang Xu; Xinfu Feng; Xiangyong Hao; Peng Wang; Yanfang Zhang; Xiaobo Zheng; Lian Li; Shengsheng Ren; Ming Zhang; Mingqing Xu
Journal:  J Exp Clin Cancer Res       Date:  2019-02-22

Review 10.  Awareness and current knowledge of breast cancer.

Authors:  Muhammad Akram; Mehwish Iqbal; Muhammad Daniyal; Asmat Ullah Khan
Journal:  Biol Res       Date:  2017-10-02       Impact factor: 5.612

View more
  4 in total

1.  miR-522 regulates cell proliferation, migration, invasion capacities and acts as a potential biomarker to predict prognosis in triple-negative breast cancer.

Authors:  Wei Wang; Wei Zhang; Jianhua Wu; Zhuchao Zhou; Jinglin Ma
Journal:  Clin Exp Med       Date:  2021-09-14       Impact factor: 5.057

2.  IncRNA MAPKAPK5-AS1 promotes proliferation and migration of thyroid cancer cell lines by targeting miR-519e-5p/YWHAH.

Authors:  Yan Zhou; Shanshan Liu; Yan Luo; Meiying Zhang; Xueling Jiang; Yan Xiong
Journal:  Eur J Histochem       Date:  2020-12-03       Impact factor: 3.188

Review 3.  Cancer Stem Cells Are Possible Key Players in Regulating Anti-Tumor Immune Responses: The Role of Immunomodulating Molecules and MicroRNAs.

Authors:  Sara Tomei; Ola Ibnaof; Shilpa Ravindran; Soldano Ferrone; Cristina Maccalli
Journal:  Cancers (Basel)       Date:  2021-04-02       Impact factor: 6.575

Review 4.  MicroRNAs, Tristetraprolin Family Members and HuR: A Complex Interplay Controlling Cancer-Related Processes.

Authors:  Cyril Sobolewski; Laurent Dubuquoy; Noémie Legrand
Journal:  Cancers (Basel)       Date:  2022-07-20       Impact factor: 6.575

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.